Preoperative Advanced Therapy Use and Anastomotic Complications After Elective Surgery for Crohn’s Disease

BACKGROUND: Whether advanced therapies should be continued before elective surgery for Crohn's disease remains uncertain because of concerns regarding postoperative infectious and anastomotic complications. We evaluated the association between preoperative advanced therapy use and postoperative anastomotic complications. STUDY DESIGN: We conducted a retrospective cohort study of patients with Crohn's disease undergoing elective colectomy or proctectomy in the 24-center NSQIP-Inflammatory Bowel Disease Collaborative from 2021-2024. Advanced therapy use within 60 days before surgery was compared with no advanced therapy. The primary outcome was anastomotic leak and/or organ space surgical site infection (AL/OSSI) within 30 days. Inverse probability of treatment weighting with institutional clustering was used to adjust for baseline differences. RESULTS: Among 1,150 patients, 740 (64%) received advanced therapy. After weighting, AL/OSSI occurred in 2.43% of patients receiving advanced therapy vs 6.46% without advanced therapy (absolute risk difference -4.03%; RR 0.38, 95% CI 0.19-0.75; p=0.01). No statistically significant differences were observed in superficial surgical site infection, deep incisional surgical site infection, or wound dehiscence. Firth penalized logistic regression demonstrated a concordant association (OR 0.46, 95% CI 0.24-0.90; p=0.02). Point estimates favored advanced therapy across examined subgroups, with no statistically significant interactions. CONCLUSIONS: Preoperative advanced therapy use was associated with lower 30-day AL/OSSI without statistically significant increases in other reported infectious or wound complications among patients with Crohn's disease undergoing elective colorectal surgery. These findings support the safety of preoperative advanced therapy continuation while warranting confirmation of the observed association with improved anastomotic outcomes.

Authors

Institutions

Publication Details

Journal
Journal of the American College of Surgeons
Published
2026-11-18
DOI
https://doi.org/10.1097/xcs.0000000000002287
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Preoperative Advanced Therapy Use and Anastomotic Complications After Elective Surgery for Crohn’s Disease

Benjamin Abbadessa, Nicole Lopez, Stefan David Holubar, Shanglei Liu et al.
2 links
Journal of the American College of Surgeons
Inflammatory Bowel Disease
article

Preoperative Advanced Therapy Use and Anastomotic Complications After Elective Surgery for Crohn’s Disease

Benjamin Abbadessa, Nicole Lopez, Stefan David Holubar, Shanglei Liu, Nicholas C. Neel, Samuel G. Eisenstein, Bard Clifford Cosman, Sonia L. Ramamoorthy, Lisa A. Parry, On behalf of the NSQIP-IBD Collaborative, Nicole Raclin, Dong-Jin “Eastern” Kang Sim
article en

Abstract

BACKGROUND: Whether advanced therapies should be continued before elective surgery for Crohn's disease remains uncertain because of concerns regarding postoperative infectious and anastomotic complications. We evaluated the association between preoperative advanced therapy use and postoperative anastomotic complications. STUDY DESIGN: We conducted a retrospective cohort study of patients with Crohn's disease undergoing elective colectomy or proctectomy in the 24-center NSQIP-Inflammatory Bowel Disease Collaborative from 2021-2024. Advanced therapy use within 60 days before surgery was compared with no advanced therapy. The primary outcome was anastomotic leak and/or organ space surgical site infection (AL/OSSI) within 30 days. Inverse probability of treatment weighting with institutional clustering was used to adjust for baseline differences. RESULTS: Among 1,150 patients, 740 (64%) received advanced therapy. After weighting, AL/OSSI occurred in 2.43% of patients receiving advanced therapy vs 6.46% without advanced therapy (absolute risk difference -4.03%; RR 0.38, 95% CI 0.19-0.75; p=0.01). No statistically significant differences were observed in superficial surgical site infection, deep incisional surgical site infection, or wound dehiscence. Firth penalized logistic regression demonstrated a concordant association (OR 0.46, 95% CI 0.24-0.90; p=0.02). Point estimates favored advanced therapy across examined subgroups, with no statistically significant interactions. CONCLUSIONS: Preoperative advanced therapy use was associated with lower 30-day AL/OSSI without statistically significant increases in other reported infectious or wound complications among patients with Crohn's disease undergoing elective colorectal surgery. These findings support the safety of preoperative advanced therapy continuation while warranting confirmation of the observed association with improved anastomotic outcomes.

Journal of the American College of Surgeons
Cleveland Clinic (US), University of California San Diego (US)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon